sorafenib has been researched along with acacetin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (acacetin) | Trials (acacetin) | Recent Studies (post-2010) (acacetin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 231 | 1 | 159 |
| Protein | Taxonomy | sorafenib (IC50) | acacetin (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.083 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.1655 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.167 | |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | 3.3 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.049 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.6967 | |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | 5.78 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 5.78 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.011 | |
| Inositol hexakisphosphate kinase 2 | Homo sapiens (human) | 5.7 | |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | 9.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Chen, LC; Hsu, KC; Huang, HL; Huang, WJ; Lien, ST; Lin, TE; Ngo, ST; Pan, SL; Sung, TY; Tseng, HJ; Wu, YW; Yen, SC | 1 |
2 other study(ies) available for sorafenib and acacetin
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Flavonoids; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |